{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/SYRE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T13:07:30.500Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1361,"canonical_name":"Spyre Therapeutics, Inc.","cik":"0001636282","uei":null,"lei":null,"duns":null,"ticker":"SYRE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":108,"clinical":3},"count":100,"timeline":[{"ts":"2026-10-09","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Spyre Therapeutics, Inc. — 2026-10-09","url_slug":"/sec/cik-0001636282/schedule-13d-a/0001104659-26-115087","accession_number":"0001104659-26-115087","importance":70},{"ts":"2026-10-07","kind":"sec.filing","form_type":"8-K","title":"8-K — Spyre Therapeutics, Inc. — 2026-10-07","url_slug":"/sec/cik-0001636282/8-k/0001628280-26-065291","accession_number":"0001628280-26-065291","importance":35},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Spyre Therapeutics, Inc.","title":"Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD","security_title":"PHASE2","status":"ENROLLING_BY_INVITATION","accession_number":"NCT07652294","excerpt":"[\"Ulcerative Colitis\",\"Inflammatory Bowel Diseases\",\"Colitis\",\"Colitis, Ulcerative\"]","importance":45},{"ts":"2026-10-06","kind":"sec.filing","form_type":"424B5","title":"424B5 — Spyre Therapeutics, Inc. — 2026-10-06","url_slug":"/sec/cik-0001636282/424b5/0001628280-26-065249","accession_number":"0001628280-26-065249","importance":30},{"ts":"2026-10-05","kind":"sec.filing","form_type":"424B5","title":"424B5 — Spyre Therapeutics, Inc. — 2026-10-05","url_slug":"/sec/cik-0001636282/424b5/0001628280-26-064924","accession_number":"0001628280-26-064924","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000117","accession_number":"0001636282-26-000117","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000118","accession_number":"0001636282-26-000118","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000119","accession_number":"0001636282-26-000119","importance":30},{"ts":"2026-10-01","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Spyre Therapeutics, Inc. — 2026-10-01","url_slug":"/sec/cik-0001636282/schedule-13g/0001104659-26-112828","accession_number":"0001104659-26-112828","importance":55},{"ts":"2026-10-01","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-10-01","url_slug":"/sec/cik-0001636282/144/0001950047-26-009971","accession_number":"0001950047-26-009971","importance":30},{"ts":"2026-10-01","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-10-01","url_slug":"/sec/cik-0001636282/144/0001950047-26-009978","accession_number":"0001950047-26-009978","importance":30},{"ts":"2026-10-01","kind":"sec.insider.16605","reporter":"King-Jones Heidy","title":"See Remarks","shares":16605,"price_per_share":90.35,"usd_value":1500262,"security_title":"Common Stock","importance":16.50026175},{"ts":"2026-10-01","kind":"sec.insider.7228","reporter":"King-Jones Heidy","title":"See Remarks","shares":7228,"price_per_share":91.35,"usd_value":660278,"security_title":"Common Stock","importance":15.6602778},{"ts":"2026-10-01","kind":"sec.insider.28933","reporter":"King-Jones Heidy","title":"See Remarks","shares":28933,"price_per_share":14.5,"usd_value":419529,"security_title":"Common Stock","importance":15.4195285},{"ts":"2026-10-01","kind":"sec.insider.2600","reporter":"King-Jones Heidy","title":"See Remarks","shares":2600,"price_per_share":93.46,"usd_value":242996,"security_title":"Common Stock","importance":15.242996},{"ts":"2026-10-01","kind":"sec.insider.2100","reporter":"King-Jones Heidy","title":"See Remarks","shares":2100,"price_per_share":92.7,"usd_value":194670,"security_title":"Common Stock","importance":15.19467},{"ts":"2026-10-01","kind":"sec.insider.400","reporter":"King-Jones Heidy","title":"See Remarks","shares":400,"price_per_share":89.24,"usd_value":35696,"security_title":"Common Stock","importance":15.035696},{"ts":"2026-09-30","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-09-30","url_slug":"/sec/cik-0001636282/144/0001950047-26-009876","accession_number":"0001950047-26-009876","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Spyre Therapeutics, Inc. — 2026-09-08","url_slug":"/sec/cik-0001636282/8-k/0001636282-26-000113","accession_number":"0001636282-26-000113","importance":35},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000107","accession_number":"0001636282-26-000107","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000109","accession_number":"0001636282-26-000109","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-09-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000111","accession_number":"0001636282-26-000111","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-09-01","url_slug":"/sec/cik-0001636282/144/0001950047-26-008970","accession_number":"0001950047-26-008970","importance":30},{"ts":"2026-08-25","kind":"sec.filing","form_type":"8-K","title":"8-K — Spyre Therapeutics, Inc. — 2026-08-25","url_slug":"/sec/cik-0001636282/8-k/0001636282-26-000105","accession_number":"0001636282-26-000105","importance":35},{"ts":"2026-08-14","kind":"clinical.trial","reporter":"Spyre Therapeutics, Inc.","title":"A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07766005","excerpt":"[\"Hidradenitis Suppurativa (HS)\"]","importance":45},{"ts":"2026-08-10","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-08-10","url_slug":"/sec/cik-0001636282/4/0001636282-26-000102","accession_number":"0001636282-26-000102","importance":30},{"ts":"2026-08-07","kind":"sec.insider.s","reporter":"Albers Jeffrey W.","title":null,"shares":10000,"price_per_share":104.68,"usd_value":1046800,"security_title":"Common Stock","importance":36.0468},{"ts":"2026-08-07","kind":"sec.insider.s","reporter":"Albers Jeffrey W.","title":null,"shares":8000,"price_per_share":104.38,"usd_value":835040,"security_title":"Common Stock","importance":35.83504},{"ts":"2026-08-07","kind":"sec.insider.s","reporter":"Albers Jeffrey W.","title":null,"shares":5000,"price_per_share":104.47,"usd_value":522350,"security_title":"Common Stock","importance":35.52235},{"ts":"2026-08-07","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001636282/144/0001950047-26-007819","accession_number":"0001950047-26-007819","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001636282/144/0001950047-26-007821","accession_number":"0001950047-26-007821","importance":30},{"ts":"2026-08-07","kind":"sec.insider.m","reporter":"Albers Jeffrey W.","title":null,"shares":5000,"price_per_share":10.39,"usd_value":51950,"security_title":"Common Stock","importance":15.05195},{"ts":"2026-08-05","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0001636282/4/0001636282-26-000099","accession_number":"0001636282-26-000099","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-08-05","url_slug":"/sec/cik-0001636282/4/0001636282-26-000100","accession_number":"0001636282-26-000100","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Spyre Therapeutics, Inc. — 2026-08-04","url_slug":"/sec/cik-0001636282/10-q/0001636282-26-000096","accession_number":"0001636282-26-000096","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Spyre Therapeutics, Inc. — 2026-08-04","url_slug":"/sec/cik-0001636282/8-k/0001636282-26-000098","accession_number":"0001636282-26-000098","importance":35},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":7157,"price_per_share":95.1,"usd_value":680631,"security_title":"Common Stock","importance":35.6806307},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":5635,"price_per_share":95.93,"usd_value":540566,"security_title":"Common Stock","importance":35.54056555},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":5100,"price_per_share":95.21,"usd_value":485571,"security_title":"Common Stock","importance":35.485571},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":2300,"price_per_share":96.3,"usd_value":221490,"security_title":"Common Stock","importance":35.22149},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":1392,"price_per_share":96.82,"usd_value":134773,"security_title":"Common Stock","importance":35.13477344},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":800,"price_per_share":93.97,"usd_value":75176,"security_title":"Common Stock","importance":35.075176},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":100,"price_per_share":97.1,"usd_value":9710,"security_title":"Common Stock","importance":35.00971},{"ts":"2026-08-03","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":16,"price_per_share":97.46,"usd_value":1559,"security_title":"Common Stock","importance":35.00155936},{"ts":"2026-08-03","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-08-03","url_slug":"/sec/cik-0001636282/144/0001950047-26-007571","accession_number":"0001950047-26-007571","importance":30},{"ts":"2026-08-03","kind":"sec.insider.m","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":7500,"price_per_share":14.5,"usd_value":108750,"security_title":"Common Stock","importance":15.10875},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000086","accession_number":"0001636282-26-000086","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000087","accession_number":"0001636282-26-000087","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001636282/4/0001636282-26-000088","accession_number":"0001636282-26-000088","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":10176,"price_per_share":87.44,"usd_value":889789,"security_title":"Common Stock","importance":35.88978944},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Sloan Sheldon","title":"Chief Medical Officer","shares":6500,"price_per_share":87.52,"usd_value":568880,"security_title":"Common Stock","importance":35.56888},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":5775,"price_per_share":87.55,"usd_value":505601,"security_title":"Common Stock","importance":35.50560125},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":4234,"price_per_share":88.12,"usd_value":373100,"security_title":"Common Stock","importance":35.37310008},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Sloan Sheldon","title":"Chief Medical Officer","shares":1834,"price_per_share":88.34,"usd_value":162016,"security_title":"Common Stock","importance":35.16201556},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":1725,"price_per_share":88.37,"usd_value":152438,"security_title":"Common Stock","importance":35.15243825},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":590,"price_per_share":88.91,"usd_value":52457,"security_title":"Common Stock","importance":35.0524569},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001636282/144/0001950047-26-006779","accession_number":"0001950047-26-006779","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Sloan Sheldon","title":"Chief Medical Officer","shares":8334,"price_per_share":27.46,"usd_value":228852,"security_title":"Common Stock","importance":15.22885164},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":7500,"price_per_share":14.5,"usd_value":108750,"security_title":"Common Stock","importance":15.10875},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001636282/4/0001853327-26-000008","accession_number":"0001853327-26-000008","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"S-3ASR","title":"S-3ASR — Spyre Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001636282/s-3asr/0001628280-26-045742","accession_number":"0001628280-26-045742","importance":30},{"ts":"2026-06-25","kind":"sec.form144","reporter":"SCOTT BURROWS","title":"Officer","shares":15000,"usd_value":1306980,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006485","importance":40.261396},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":10000,"price_per_share":87.14,"usd_value":871400,"security_title":"Common Stock","importance":35.8714},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":5000,"price_per_share":87.12,"usd_value":435600,"security_title":"Common Stock","importance":35.4356},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001636282/144/0001950047-26-006485","accession_number":"0001950047-26-006485","importance":30},{"ts":"2026-06-25","kind":"sec.insider.10000","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":10000,"price_per_share":87.14,"usd_value":871400,"security_title":"Common Stock","importance":15.8714},{"ts":"2026-06-25","kind":"sec.insider.5000","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":5000,"price_per_share":87.12,"usd_value":435600,"security_title":"Common Stock","importance":15.4356},{"ts":"2026-06-25","kind":"sec.insider.m","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":15000,"price_per_share":14.5,"usd_value":217500,"security_title":"Common Stock","importance":15.2175},{"ts":"2026-06-25","kind":"sec.insider.15000","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":15000,"price_per_share":14.5,"usd_value":217500,"security_title":"Common Stock","importance":15.2175},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Fairmount Funds Management LLC","title":"","shares":4684781,"price_per_share":85.31,"usd_value":399658667,"security_title":"Common Stock","importance":75},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Fairmount Healthcare Fund II L.P.","title":"","shares":4684781,"price_per_share":85.31,"usd_value":399658667,"security_title":"Common Stock","importance":75},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Kiselak Tomas","title":"","shares":4684781,"price_per_share":85.31,"usd_value":399658667,"security_title":"Common Stock","importance":75},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Harwin Peter Evan","title":"","shares":4684781,"price_per_share":85.31,"usd_value":399658667,"security_title":"Common Stock","importance":75},{"ts":"2026-06-23","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — Spyre Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001636282/schedule-13d-a/0001104659-26-076961","accession_number":"0001104659-26-076961","importance":70},{"ts":"2026-06-23","kind":"sec.insider.4684781","reporter":"Fairmount Funds Management LLC","title":null,"shares":4684781,"price_per_share":85.31,"usd_value":399658667,"security_title":"Common Stock","importance":55},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001636282/144/0001104659-26-076969","accession_number":"0001104659-26-076969","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001636282/4/0001104659-26-076967","accession_number":"0001104659-26-076967","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001636282/4/0001636282-26-000084","accession_number":"0001636282-26-000084","importance":30},{"ts":"2026-06-23","kind":"sec.insider.666680","reporter":"Fairmount Funds Management LLC","title":null,"shares":666680,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-23","kind":"sec.insider.c","reporter":"Fairmount Funds Management LLC","title":"","shares":666680,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-23","kind":"sec.insider.c","reporter":"Fairmount Healthcare Fund II L.P.","title":"","shares":666680,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-23","kind":"sec.insider.c","reporter":"Kiselak Tomas","title":"","shares":666680,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-23","kind":"sec.insider.c","reporter":"Harwin Peter Evan","title":"","shares":666680,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-22","kind":"sec.form144","reporter":"MICHAEL HENDERSON","title":"Director","shares":20000,"usd_value":1766800,"security_title":"Common","approx_sale_date":"2026-06-22","accession_number":"0001950047-26-006375","importance":40.35336},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"HENDERSON MICHAEL THOMAS","title":null,"shares":20000,"price_per_share":100,"usd_value":2000000,"security_title":"Common Stock","importance":37},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001636282/144/0001950047-26-006375","accession_number":"0001950047-26-006375","importance":30},{"ts":"2026-06-22","kind":"sec.insider.20000","reporter":"HENDERSON MICHAEL THOMAS","title":null,"shares":20000,"price_per_share":100,"usd_value":2000000,"security_title":"Common Stock","importance":17},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Spyre Therapeutics, Inc. — 2026-06-15","url_slug":"/sec/cik-0001636282/8-k/0001636282-26-000083","accession_number":"0001636282-26-000083","importance":35},{"ts":"2026-06-03","kind":"sec.form144","reporter":"SHELDON SLOAN","title":"Officer","shares":16667,"usd_value":1152690,"security_title":"Common","approx_sale_date":"2026-06-03","accession_number":"0001950047-26-005572","importance":40.230537944},{"ts":"2026-06-03","kind":"sec.insider.s","reporter":"Sloan Sheldon","title":"Chief Medical Officer","shares":8333,"price_per_share":75,"usd_value":624975,"security_title":"Common Stock","importance":35.624975},{"ts":"2026-06-03","kind":"sec.filing","form_type":"144","title":"144 — Spyre Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001636282/144/0001950047-26-005572","accession_number":"0001950047-26-005572","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000076","accession_number":"0001636282-26-000076","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000077","accession_number":"0001636282-26-000077","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Spyre Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001636282/4/0001636282-26-000078","accession_number":"0001636282-26-000078","importance":30},{"ts":"2026-06-03","kind":"sec.insider.m","reporter":"Sloan Sheldon","title":"Chief Medical Officer","shares":8333,"price_per_share":27.46,"usd_value":228824,"security_title":"Common Stock","importance":15.22882418},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":8149,"price_per_share":70.5,"usd_value":574505,"security_title":"Common Stock","importance":35.5745045},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":3557,"price_per_share":69.4,"usd_value":246856,"security_title":"Common Stock","importance":35.2468558},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Turtle Cameron","title":"Chief Executive Officer","shares":3294,"price_per_share":71.38,"usd_value":235126,"security_title":"Common Stock","importance":35.23512572},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":3100,"price_per_share":72.06,"usd_value":223386,"security_title":"Common Stock","importance":35.223386},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Burrows Scott L","title":"Chief Financial Officer","shares":2599,"price_per_share":70.77,"usd_value":183931,"security_title":"Common Stock","importance":35.18393123}]}